Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company founded in 2018 and headquartered in the United States. The company's slogan, "Discovering therapies to change the trajectory of neurodegenerative disease," reflects its focus on leveraging new insights into progranulin and lysosomal biology to develop medicines for neurodegenerative diseases. In its latest funding round in February 2022, Arkuda Therapeutics secured a substantial $64.00M Series B investment. This funding was supported by an impressive group of investors including Atlas Venture, Pivotal bioVenture Partners, Cormorant Asset Management, Eli Lilly, Mission BioCapital, Tekla Capital, Pfizer Venture Investments, and Surveyor Capital. Arkuda Therapeutics' innovative approach to tackling neurodegenerative diseases, coupled with the strong support from renowned investors, positions the company as a promising player in the biotechnology, healthcare, and pharmaceutical industries. By targeting a pressing medical need with a novel therapeutic approach, Arkuda Therapeutics demonstrates significant potential for future growth and impact on addressing neurodegenerative diseases.